535 related articles for article (PubMed ID: 21169548)
21. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.
Zou P; Liu W; Chen YH
Int Immunopharmacol; 2005 Apr; 5(4):631-5. PubMed ID: 15710332
[TBL] [Abstract][Full Text] [Related]
22. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
[TBL] [Abstract][Full Text] [Related]
23. M2e-based universal influenza A vaccine.
Fiers W; De Filette M; El Bakkouri K; Schepens B; Roose K; Schotsaert M; Birkett A; Saelens X
Vaccine; 2009 Oct; 27(45):6280-3. PubMed ID: 19840661
[TBL] [Abstract][Full Text] [Related]
24. Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective.
De Filette M; Ysenbaert T; Roose K; Schotsaert M; Roels S; Goossens E; Schepens B; Fiers W; Saelens X
J Gen Virol; 2011 Feb; 92(Pt 2):301-6. PubMed ID: 20965983
[TBL] [Abstract][Full Text] [Related]
25. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens.
Zhang X; Liu M; Liu C; Du J; Shi W; Sun E; Li H; Li J; Zhang Y
Intervirology; 2011; 54(5):290-9. PubMed ID: 21228535
[TBL] [Abstract][Full Text] [Related]
27. Improved design and intranasal delivery of an M2e-based human influenza A vaccine.
De Filette M; Fiers W; Martens W; Birkett A; Ramne A; Löwenadler B; Lycke N; Jou WM; Saelens X
Vaccine; 2006 Nov; 24(44-46):6597-601. PubMed ID: 16814430
[TBL] [Abstract][Full Text] [Related]
28. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice.
Zhou C; Zhou L; Chen YH
Vaccine; 2012 May; 30(23):3463-9. PubMed ID: 22446634
[TBL] [Abstract][Full Text] [Related]
29. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
[TBL] [Abstract][Full Text] [Related]
30. [Cowpea mosaic virus chimeric particles bearing ectodomain of matrix protein 2 (M2E) of influenza A virus: production and characteristics].
Meshcheriakova IuA; El'darov MA; Migunov AI; Stepanova LA; Repko IA; Kiselev OI; Lomonosov DP; Skriabin KG
Mol Biol (Mosk); 2009; 43(4):741-50. PubMed ID: 19807038
[TBL] [Abstract][Full Text] [Related]
31. A "universal" human influenza A vaccine.
Fiers W; De Filette M; Birkett A; Neirynck S; Min Jou W
Virus Res; 2004 Jul; 103(1-2):173-6. PubMed ID: 15163506
[TBL] [Abstract][Full Text] [Related]
32. Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.
Lee YN; Kim MC; Lee YT; Hwang HS; Lee J; Kim C; Kang SM
PLoS One; 2015; 10(9):e0137822. PubMed ID: 26366729
[TBL] [Abstract][Full Text] [Related]
33. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
[TBL] [Abstract][Full Text] [Related]
34. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.
Zharikova D; Mozdzanowska K; Feng J; Zhang M; Gerhard W
J Virol; 2005 Jun; 79(11):6644-54. PubMed ID: 15890902
[TBL] [Abstract][Full Text] [Related]
35. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
Wang W; Huang B; Wang X; Tan W; Ruan L
Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
[TBL] [Abstract][Full Text] [Related]
36. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus.
Fu TM; Freed DC; Horton MS; Fan J; Citron MP; Joyce JG; Garsky VM; Casimiro DR; Zhao Q; Shiver JW; Liang X
Virology; 2009 Mar; 385(1):218-26. PubMed ID: 19070878
[TBL] [Abstract][Full Text] [Related]
37. Protection against homo and hetero-subtypic influenza A virus by optimized M2e DNA vaccine.
Yao Y; Wang H; Chen J; Shao Z; He B; Chen J; Lan J; Chen Q; Chen Z
Emerg Microbes Infect; 2019; 8(1):45-54. PubMed ID: 30866759
[TBL] [Abstract][Full Text] [Related]
38. A universal influenza A vaccine based on the extracellular domain of the M2 protein.
Neirynck S; Deroo T; Saelens X; Vanlandschoot P; Jou WM; Fiers W
Nat Med; 1999 Oct; 5(10):1157-63. PubMed ID: 10502819
[TBL] [Abstract][Full Text] [Related]
39. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
[TBL] [Abstract][Full Text] [Related]
40. Characterization of immunity induced by M2e of influenza virus.
Wu F; Huang JH; Yuan XY; Huang WS; Chen YH
Vaccine; 2007 Dec; 25(52):8868-73. PubMed ID: 18061317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
